<SEC-DOCUMENT>0001140361-22-037240.txt : 20221014
<SEC-HEADER>0001140361-22-037240.hdr.sgml : 20221014
<ACCEPTANCE-DATETIME>20221014163349
ACCESSION NUMBER:		0001140361-22-037240
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20221008
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221014
DATE AS OF CHANGE:		20221014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		221311672

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10042946_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:btx="http://brooklynitx.com/20221008" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finacial Solutions inc.
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_68b7d76f7f964222ab460f4b1530167e" contextRef="c20221008to20221008" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_33f2264cff6a4e068e2bf7c04c77161c" contextRef="c20221008to20221008">0000748592</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="btx-20221008.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20221008to20221008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-08</xbrli:startDate><xbrli:endDate>2022-10-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_de22f9a747f64db399e4bfbc99373a61" contextRef="c20221008to20221008">8-K</ix:nonNumeric></div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_0969f57d8dba4f4d9e804a5a0b9c93ec" contextRef="c20221008to20221008" format="ixt:date-monthname-day-year-en">October 8, 2022</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_7b2ab6666e8d493abc0389dc286f6673" contextRef="c20221008to20221008">Brooklyn ImmunoTherapeutics, Inc.</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.61%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_4a367ad333b5400bb9e60812b94cdb1a" contextRef="c20221008to20221008" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33.68%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_16058f036b7a4c56ac6b861efd7d7beb" contextRef="c20221008to20221008">001-11460</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_d5c2085f6b0947fd9b68b1b037a58791" contextRef="c20221008to20221008">31-1103425</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 32.61%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 33.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_7cc25fa170bd49ba8eea86a14f8821c0" contextRef="c20221008to20221008">10355 Science Center Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_ce12040db0414e1ebea5ae53da46be6b" contextRef="c20221008to20221008">Suite 150</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_188fe3964e4446ad8a7d9f79662cb0a3" contextRef="c20221008to20221008">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_889df62cb9274fa8bf3cd168b926ecf0" contextRef="c20221008to20221008" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_8daa3f82782c49968167aa9e5df89040" contextRef="c20221008to20221008">92121</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Address of Principal Executive Offices)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_32794a5444c245cf907152a0b35b715f" contextRef="c20221008to20221008">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_58726bb3ec3c4757bd218a30e348599c" contextRef="c20221008to20221008">582-1199</ix:nonNumeric></span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_822153b6f2c2418e8771c417de6c8386" contextRef="c20221008to20221008" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_c3ec0441730842f2a0e9b73c3114d70f" contextRef="c20221008to20221008" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_cd48834c5e474c209cbfdb1e57f86e9e" contextRef="c20221008to20221008" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_187f122d6c6f408a91d256c12475c5b6" contextRef="c20221008to20221008" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">Trading symbol</div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_a77112c38be84e23b79341fee77f1241" contextRef="c20221008to20221008">Common Stock, par value $0.005 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_840ee01ddc6445bf95352561d98dce9c" contextRef="c20221008to20221008">BTX</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_6410edff7a5f4a558a24a1ab285f61f1" contextRef="c20221008to20221008" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities
        Exchange Act of 1934:</div>

      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_f4ec674725eb4bc9bd6ed98c60e6be12" contextRef="c20221008to20221008" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </span></div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
        <div>
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Entry into a Material Definitive Agreement.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On October 8, 2022, Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline;">Company</span>&#8221;), entered into
          an option agreement (the &#8220;<span style="text-decoration: underline;">Option Agreement</span>&#8221;) with Exacis Biotherapeutics, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline;">Exacis</span>&#8221;), pursuant to which Exacis granted the Company the option to negotiate and enter into an exclusive worldwide license to
          certain of the technology licensed by Exacis for the treatment of cancer in humans (the &#8220;<span style="text-decoration: underline;">Option</span>&#8221;). The Option Agreement provides that the Company will pay Exacis a fee of $250,000 for the Option, which would be creditable against the fees
          or purchase price payable under any such license if entered into by the Company in accordance with Option Agreement. The Option Agreement provides for certain payments upon the execution of a definitive license agreement, which would become
          payable only upon execution, and in accordance with the terms, of the applicable license agreement, if any.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">&#160;</div>

      </div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The foregoing description of the Option Agreement is only a summary and is qualified in its entirety by reference
          to the full text of the Option Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 1.01.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d)</div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Exhibits.</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div>
              </div>
            </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: center;">
              <div>
                <div style="font-weight: bold;">Description</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><a href="brhc10042946_10-1.htm">10.1*</a></div>
            </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Option Agreement, dated October 8, 2022, by and between Exacis Biotherapeutics, Inc. and Brooklyn ImmunoTherapeutics, Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;">104</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 90%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">*</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color: rgb(0, 0, 0);">Pursuant to Item
            601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise disclosed in such
            exhibit. The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and Exchange Commission or its staff upon request.</span></span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div><br />
        </div>

      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
        duly authorized.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 50%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>&#160;</div>
              </td>

    <td style="font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1" colspan="3">
                <div>
                  <div style="text-align: left; font-variant: small-caps;">Brooklyn ImmunoTherapeutics, Inc.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>&#160;</div>
              </td>

    <td style="font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1" colspan="3">
                <div>&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>
                  <div style="text-align: left;">Dated: October 14<span style="color: rgb(0, 0, 0);">, 2022</span></div>
                </div>
              </td>

    <td style="width: 3%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>
                  <div style="text-align: left;">By:</div>
                </div>
              </td>

    <td style="width: 37%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <div>
                  <div style="text-align: left;">/s/ Andrew Jackson</div>
                </div>
              </td>

    <td style="width: 10%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>&#160;</div>
              </td>

    <td style="width: 3%; font-family: 'Times New Roman'; font-size: 10pt;">
                <div>&#160;</div>
              </td>

    <td style="font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
                <div>
                  <div style="text-align: left;">Chief Financial Officer</div>
                </div>
              </td>

  </tr>


</table>
        <div> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </span></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10042946_10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 22.10.1.5080
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
  <!--PROfilePageNumberReset%Num%1%-%-%-->
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 10.1</font><br>
  </div>
  <div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">OPTION AGREEMENT</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">This Option Agreement (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;) is made and entered into as of
      October 8, 2022 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Effective Date</u></font>&#8221;), by and between Exacis Biotherapeutics, Inc., a corporation organized and existing under the laws of Delaware (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rights Holder</u></font>&#8221;), and Brooklyn ImmunoTherapeutics, Inc. (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;). Company and Rights Holder each
      may be referred to herein individually as a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Party</u></font>&#8221; or collectively as the &#8220;Parties.&#8221;</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BACKGROUND</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">WHEREAS</font>, Rights Holder is the exclusive licensee of the
      &#8220;Rights Holder Technology,&#8221; with the right to &#8220;Exploit&#8221; &#8220;Licensed Products&#8221; using the Rights Holder Technology in the &#8220;Territory&#8221; in the &#8220;Field&#8221; (as each of said terms is defined below) and the right to grant sublicenses with respect thereto pursuant
      to the Exclusive License Agreement between Rights Holder and Factor Bioscience Limited (&#8220;Factor&#8221;) entered into as of November 4, 2020 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Factor License</u></font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;); and</div>
    <div style="text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">WHEREAS</font>, Rights Holder wishes to grant, and Company wishes to
      receive, an option for an exclusive license under Rights Holder Technology in the Field and the Territory, all on the terms and subject to the conditions set forth in this Agreement;</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">NOW, THEREFORE</font>, in consideration of the foregoing premises
      and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Definitions</font>. For purposes of this Agreement, the following terms when used with initial capital letters shall have the respective meanings set forth below in this Section 1 or elsewhere
        herein.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Affiliate</u></font>&#8221; means, with respect to either Party, any person, corporation or other business entity that, directly or indirectly through one or more intermediaries, actually controls, is actually
        controlled by, or is under common control with such Party. As used in this Section 1.1, "control" means to possess, directly or indirectly, the power to affirmatively direct the management and policies of such person, corporation or other business
        entity, whether through ownership of voting securities, by contract or otherwise.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Auxiliary Technology Patents</u></font>&#8221; means (a) the patents and patent applications set forth on Exhibit C, and (b) any reissue, divisional, continuation, continuation in part, reexamination, renewal,
        extension or supplementary protection certificate for each of the patents and patent applications set forth on Exhibit C, (c) the Improvement Patents, and (d) any reissue, divisional, continuation, continuation in part, reexamination, renewal,
        extension supplementary protection certificate for each of the Improvement Patents, including all U.S. and foreign and international counterparts and related patents and patent applications either now pending or pending in the future, but only to
        the extent that each of the foregoing in clauses (a), (b), (c) and (d) are Controlled by Rights Holder.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>CAR</u></font>&#8221; means a chimeric antigen receptor expressed with specific and defined molecular architecture and signaling domain sequences.</font></div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-1-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Cell Line</u></font>&#8221; means a human pluripotent stem cell line generated using the cell reprogramming methods disclosed in the Rights Holder Patents.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.5</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Confidential Information</u></font>&#8221; means all information and know-how and any tangible embodiments thereof and other materials provided by or on behalf of one Party to the other Party either in connection
        with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement (including any consulting work that may be undertaken by Rights Holder on behalf of the Company, as mutually agreed upon by the Parties
        from time-to- time) or that otherwise relates to the Rights Holder Technology or Cell Lines, whether disclosed orally, visually, electronically, in writing or in other tangible or intangible form, and which may include data, knowledge, practices,
        processes, ideas, research plans, antibodies, small molecules, compounds, targets, biological and chemical formulations, structures and designs, laboratory notebooks, proof of concept and pre-clinical studies, formulation or manufacturing processes
        and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel matters relating to the disclosing Party or to its present or future products, sales, suppliers, customers, employees, investors or business;
        provided, that, information, materials or know-how of a Party will not be deemed Confidential Information of such Party for purposes of this Agreement if such information, materials or know-how: (a) was already known to the receiving Party, other
        than under an obligation of confidentiality or non-use, at the time of disclosure to such receiving Party, as can be shown by written records; (b) was generally available or known to parties reasonably skilled in the field to which such information
        or know-how pertains, or was otherwise part of the public domain, at the time of its disclosure to such receiving Party; (c) became generally available or known to parties reasonably skilled in the field to which such information or know- how
        pertains, or otherwise became part of the public domain, after its disclosure to such receiving Party through no fault of the receiving Party; (d) was disclosed to such receiving Party, other than under an obligation of confidentiality or non-use,
        by a third party who had no obligation to the disclosing Party not to disclose such information or know-how to others; or (e) was independently discovered or developed by such receiving Party, as can be shown by their written records, without the
        use of Confidential Information belonging to the disclosing Party and prior to any subsequent disclosure by the receiving Party.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Control</u></font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Controlled by</u></font>&#8221; means, in the context of a license to or ownership of the Rights Holder Technology, the
        ability on the part of Rights Holder to grant access to or a license or sublicense of such Rights Holder Technology as provided for herein without violating the terms of the Factor License Agreement.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.7</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Cover</u></font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Covered</u></font>&#8221; means that the use, manufacture, sale, offer for sale, research, development, commercialization,
        importation or other commercial Exploitation of the subject matter in question by an unlicensed entity: (a) would infringe an issued or pending claim of a Rights Holder Patent or Auxiliary Technology Patent, or (b) incorporates, encompasses,
        references, uses or otherwise relies upon the Rights Holder Technology.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Edit</u></font>&#8221; means one or more mutations that inactivate a specific combination of human genes and/or insert one or more nucleic acid sequences that encode a specific combination of biomolecules that are
        each identified by a GenBank accession number or similar information, or by their amino acid or nucleic acid sequences.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Engineered NK Cells</u></font>&#8221; means a population of natural killer (NK) cells derived from a Cell Line, having a set of specific, defined, and experimentally validated biologic attributes, produced using the
        Rights Holder Technology, and containing at least one Edit and/or</font> expressing one or more CAR constructs selected by Company in accordance with the License Agreement. </div>
    <div style="text-align: left; margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-2-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.10</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Engineered T Cells</u></font>&#8221; means a population of T-cells derived from a Cell Line, having a set of specific, defined, and experimentally validated biologic attributes, produced using the Rights Holder
        Technology, and containing at least one Edit and/or expressing one or more CAR constructs selected by Company in accordance with the License Agreement.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 72pt;"><font style="font-weight: bold;">1.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise Notice</u></font>&#8221; has the meaning set
      forth in Section 4.</div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.12</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exploit</u></font>&#8221; and &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exploitation</u></font>&#8221; mean to develop, make, have made, manufacture, research, use, sell, have sold, offer for sale,
        commercialize, distribute, import and export.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 72pt;"><font style="font-weight: bold;">1.13&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Field</u></font>&#8221; means the treatment of cancer in
        humans.</div>
    </div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 72pt;"><font style="font-weight: bold;">1.14&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>License Agreement</u></font>&#8221; has the meaning set
        forth in Section 4.</div>
    </div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.15</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Licensed Product</u></font>&#8221; means any Covered product comprising Engineered NK Cells and/or Engineered T Cells derived from a Cell Line for use in the Field.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 72pt;"><font style="font-weight: bold;">1.16</font> &#160; &#160; &#160;&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Option Fee</u></font>&#8221; means Two Hundred Fifty
        Thousand Dollars ($250,000).</div>
    </div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 72pt;"><font style="font-weight: bold;">1.17</font> &#160; &#160;&#160; &#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Option</u></font>&#8221; has the meaning set forth in
        Section 3.</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.18</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Option Period</u></font>&#8221; means the period beginning on the Effective Date and ending on the Termination Date.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.19</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rights Holder Know-How</u></font>&#8221; means all unpatented inventions, technology, methods, materials (including biological and pharmaceutical materials), know-how, studies, pre- clinical and clinical data
        (including toxicology and safety data), tests and assays, reports, manufacturing processes, regulatory filings (including drafts) and approvals and other information Controlled by Rights Holder as of the Effective Date or thereafter, in each case
        that relates to the subject matter claimed by the Rights Holder Patents or Auxiliary Technology Patents and is necessary or useful to make, use or sell Licensed Products in the Field in the Territory.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.20</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rights Holder Patents</u></font>&#8221; means (a) the patents and patent applications set forth on Exhibit B, and (b) any reissue, divisional, continuation, continuation in part, reexamination, renewal, extension or
        supplementary protection certificate for each of the patents and patent applications set forth on Exhibit B including all U.S. and foreign and international counterparts and related patents and patent applications either now pending or pending in
        the future, but only to the extent that each of the foregoing in clauses (a) and (b) are Controlled by Rights Holder.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.21</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rights Holder Technology</u></font>&#8221; means the Rights Holder Know-How, the Rights Holder Patents, Cell-Lines and the Auxiliary Technology Patents.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.22</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Termination Date</u></font>&#8221; means December 31, 2022 unless extended by mutual written agreement of Rights Holder and Company.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 72pt;"><font style="font-weight: bold;">1.23&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Territory</u></font>&#8221; means Earth.</div>
    </div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-3-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Option Fee</font>. In consideration for the Option granted to Company hereunder, Company shall pay Rights Holder the Option Fee via wire transfer of immediately available funds on or before the
        Termination Date, provided that this Agreement is not terminated by Company pursuant to Section 9.2 below. In the event that Company has paid the Option Fee and this Agreement is terminated by Company pursuant to Section 9.2 of this Agreement,
        Rights Holder shall refund the Option Fee to Company within five (5) business days after the effective date of such termination. The Option Fee shall otherwise be non-refundable.</font></div>
    <div style="text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Option</font>. In consideration for the Option Fee, Rights Holder hereby grants to Company a right for Company to negotiate and enter into an exclusive license (with a right to sublicense) under
        the Rights Holder Technology to Exploit up to four (4) Licensed Products in the Field in the Territory (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Option</u></font>&#8221;).</font></div>
    <div style="text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exercise of Option. </font>Subject to Company&#8217;s payment of the Option Fee in accordance with Section 2, during the Option Period Company shall have the right, but not the obligation, within its
        sole discretion, to exercise the Option by delivering written notice of such exercise (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise Notice</u></font>&#8221;) to Rights Holder. Upon such delivery, Rights Holder and
        Company shall in good faith negotiate and, unless this Agreement is terminated in accordance with the termination provisions set forth in this Agreement or as otherwise determined by Company in its sole discretion, enter into an exclusive license
        agreement incorporating the terms set forth in <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit A</u></font> and granting to Company the exclusive (even as to Rights Holder) license under the Rights Holder Technology to
        Exploit Licensed Products in the Field in the Territory (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>License</u></font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;). The License
        Agreement will include terms customary to transactions of this nature as mutually agreed between the Company and Rights Holder and that are consistent with the terms of the Factor License Agreement. The License Agreement will also include (i) the
        Company's ability to obtain a license to additional Rights Holder's Technology developed now or in the future that is necessary or useful for Company to Exploit Licensed Products, and (ii) the Company&#8217;s right to acquire the Factor License Agreement
        and/or the entire business of Rights Holder, including all of the assets and/or equity securities of Rights Holder, on terms to be set forth in the License Agreement. The Option Fee shall be credited against the first fees payable under the License
        Agreement and/or the purchase price under (ii) above.</font></div>
    <div style="text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Due Diligence; Option Period Obligations</font>. Until the earlier of (i) the expiration of the Option Period or (ii) execution of the License Agreement, and subject at all times to the
        obligations of confidentiality and non-use set forth in Section 7 of this Agreement, Rights Holder will furnish reasonable access at reasonable times to the Rights Holder Technology for the limited purpose of facilitating Company&#8217;s evaluation of
        the Rights Holder Technology in the Field, as Company, its representatives or agents, may reasonably request. Rights Holder agrees that during the Option Period, Rights Holder shall: (i) perform its obligations under the Factor License Agreement,
        (ii) provide written notice to Company within five (5) business days after (A) any amendment, restatement, waiver or other change in the terms of the Factor License Agreement, (B) becoming aware of any infringement or other claim asserted by a
        third party based on Exploitation of the Rights Holder Technology, or becoming aware of any infringement of the Rights Holder Technology by a third party, or any breach of the Factor License Agreement by Factor or Rights Holder, or (C) any material
        change in the scope or extent of the Rights Holder Technology.</font></div>
    <div style="text-indent: 36pt;">&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-weight: bold;">6.&#160;&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Representations and Warranties;
          Limitation of Liability</font>.</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;6.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Representations and Warranties of Rights Holder</u></font>. Rights Holder represents and warrants to Company as follows:</font></div>
    <br>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-4-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.1.1</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Rights Holder has full power and
        authority to execute, deliver and perform this Agreement. This Agreement constitutes the legally binding and valid obligation of Rights Holder, enforceable in accordance with its terms, except as such enforcement may be limited by applicable
        bankruptcy, moratorium and other laws affecting creditors&#8217; rights generally.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.1.2</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The execution, delivery and
        performance by Rights Holder of this Agreement and the consummation of the transactions contemplated hereby will not result in any violation of, conflict with, result in a breach of or constitute a default under any contract or agreement to which
        Rights Holder is a party.</font></div>
    <div style="text-indent: 108pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.1.3</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">There are no liens or other
        encumbrances on the Rights Holder Technology or any part thereof which would interfere with the rights contemplated hereunder to be granted to Company under the License Agreement.</font></div>
    <div style="text-indent: 108pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.1.4</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">There is no action, suit,
        proceeding or investigation pending or, to Rights Holder&#8217;s knowledge, currently threatened in writing against or affecting Rights Holder that questions the validity of this Agreement or the right of Rights Holder to enter into this Agreement or
        consummate the transactions contemplated hereby, and the Factor License Agreement is in full force and effect, has not been amended and neither Rights Holder nor, to Rights Holder&#8217;s knowledge, Factor, is in breach of the Factor License Agreement.
        To Rights Holder&#8217;s knowledge, there is no basis for the foregoing.</font></div>
    <div style="text-indent: 108pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.1.5</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">To Rights Holder&#8217;s knowledge: (i)
        the patents forming part of the Rights Holder Patents and Auxiliary Technology Patents are valid and enforceable, (ii) the Rights Holder Technology has not been and is not being infringed, misappropriated or otherwise violated by any third party,
        (iii) the Exploitation of the Rights Holder Technology, whether by Factor or Rights Holder, has not infringed, misappropriated or otherwise violated any intellectual property rights of any third party and the Exploitation of the Rights Holder
        Technology by Company in compliance with the License Agreement will not infringe, misappropriate or otherwise violate any intellectual property rights of any third party, (iv) there is no action, suit, proceeding or investigation pending, or to
        Rights Holder's knowledge, currently threatened in writing against or affecting (A) Rights Holder's ability to Exploit the Rights Holder Technology, (B) the validity or enforceability of the patents or trade secrets forming part of the Rights
        Holder Technology, or (C) the ownership of the Rights Holder Technology.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Representations and Warranties of Company</u></font>. Company represents and warrants to Rights Holder as follows:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.2.1</font>&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Company has full power and
        authority to execute, deliver and perform this Agreement. This Agreement constitutes the legally binding and valid obligations of Company, enforceable in accordance with their terms, except as such enforcement may be limited by applicable
        bankruptcy, moratorium and other laws affecting creditors&#8217; rights generally.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.2.2</font>&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The execution, delivery and
        performance by Company of this Agreement and the consummation of the transactions contemplated thereby will not result in any violation of, conflict with, result in a breach of or constitute a default under any contract or agreement material to
        Company, its business or its assets.</font></div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-5-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>DISCLAIMER; LIMITATION OF LIABILITY</u></font>. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, RIGHTS HOLDER IS PROVIDING THE RIGHTS HOLDER TECHNOLOGY &#8220;AS IS.&#8221; EXCEPT AS EXPRESSLY PROVIDED IN THIS</font>
      AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS, EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE
      OR NON-INFRINGEMENT OR ASSUMES ANY RESPONSIBILITIES WHATSOEVER WITH RESPECT TO USE, SALE, OR OTHER DISPOSITION OF LICENSED PRODUCTS INCORPORATING OR MADE BY USE OR PRACTICE OF THE RIGHTS HOLDER TECHNOLOGY. WITH THE EXCEPTION OF DAMAGES ATTRIBUTABLE
      TO A PARTY&#8217;S BREACH OF SECTION 7.1, FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, IN NO EVENT WILL EITHER PARTY, OR ITS AFFILIATES, DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS, BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, INCIDENTAL,
      CONSEQUENTIAL OR INDIRECT DAMAGES OF ANY KIND, WHETHER GROUNDED IN TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, CONTRACT OR OTHERWISE. </div>
    <div>&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 36pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; Confidentiality</div>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">7.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Disclosure and Use Restriction</u></font>. Except as expressly provided herein or in any License Agreement executed pursuant hereto, the Parties agree that, for the Option Period and at all times thereafter,
        each Party will keep completely confidential and will not publish, submit for publication or otherwise disclose, and will not use for any purpose except for the purposes contemplated by this Agreement, any Confidential Information received from the
        other Party.</font></div>
    <div style="text-indent: 72pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">7.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Authorized Disclosure</u></font>. Each Party may disclose Confidential Information of the other Party to the extent that such disclosure is:</font></div>
    <div style="text-align: justify;">&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> (a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">made in response to a valid
        order of a court of competent jurisdiction; provided, however, that in each case such disclosing Party will first have given notice to the other Party and given such other Party a reasonable opportunity to take appropriate action and cooperate with
        such other Party as necessary to obtain an appropriate protective order; provided, further, that in each case, the Confidential Information disclosed in response to such court or governmental order will be limited to that information which is
        legally required to be disclosed in response to such court or governmental order, as determined in good faith by counsel to the Party that is obligated to disclose Confidential Information pursuant to such order;</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">otherwise required by law or
        regulation or the requirements of any stock exchange to which a Party is subject; provided, however, that the Party that is so required will provide such other Party with at least three (3) business days&#8217; notice of such disclosure in advance
        thereof, shall consider in good faith any comments that may be provided by such other Party in response to such disclosure, and shall take reasonable measures to assure confidential treatment of such information;</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">made by such Party, in connection
        with the performance of this Agreement or any License Agreement executed pursuant hereto, to such Party&#8217;s Affiliates, sublicensees, directors, officers, employees, consultants, representatives or agents, or to other third parties, in each case on a
        need to know basis and solely to use such information for business purposes relevant to this Agreement, and provided that each individual and entity to whom such Confidential Information is disclosed is bound in writing to non-use and
        non-disclosure obligations at least as restrictive as those set forth in this Agreement; or</font></div>
    <div style="text-align: justify; text-indent: 117pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-6-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">made by such Party to existing or
        potential acquirers, existing or potential collaborators, investment bankers, accountants, attorneys, existing or potential investors,</font> merger candidates, partners, venture capital firms or other financial institutions or investors for use of
      such information for business purposes relevant to this Agreement or for due diligence in connection with the financing, licensing or acquisition of such Party, and provided that such Party provides the disclosing Party with at least three (3)
      business days&#8217; notice of such disclosure in advance thereof, each individual and entity to whom such Confidential Information is disclosed is bound in writing to non-use and non-disclosure obligations (or in the case of attorneys, an equivalent
      professional duty of confidentiality) at least as restrictive as those set forth in this Agreement, and such Party shall remain responsible and liable to the disclosing Party for any breaches of this Agreement by such individuals or entities to whom
      such Confidential Information may be disclosed. </div>
    <div>&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Notwithstanding the foregoing, the Parties hereby agree that they will release a mutually agreed upon press release within five (5) days of the execution of this
      Agreement.</div>
    <div>&#160;</div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 36pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; Indemnification</div>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">8.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnification of Company</u></font>. Rights Holder will indemnify Company and each of its directors, officers, employees and agents (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company
            Parties</u></font>&#8221;) and defend and hold each of them harmless, from and against any and all third party claims and all related losses, damages, liabilities, costs and expenses (including reasonable attorneys&#8217; fees and expenses) (collectively,
        &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Losses</u></font>&#8221;) to the extent arising from or occurring as a result of or in connection with a breach by Rights Holder of any of its representations, warranties, covenants or
        agreements set forth in this Agreement. Notwithstanding the foregoing, Rights Holder will have no obligations under this Section 8.1 to the extent Losses arise from or occur as a result of or in connection with the (a) gross negligence or willful
        misconduct (including non-compliance with any applicable laws) on the part of a Company Party, or (b) breach by Company of any of its representations, warranties, covenants, or agreements set forth in this Agreement.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">8.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnification of Rights Holder</u></font>. Company will indemnify Rights Holder, its Affiliates and each of their directors, officers, employees and agents (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rights Holder</u></font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Parties</u></font>&#8221;), and defend and hold each of them harmless, from and against any and all third party claims and all related Losses to
        the extent arising from or occurring as a result of or in connection with Company performing its obligations under this Agreement, or a breach by Company of any of its representations, warranties, covenants or agreements set forth in this
        Agreement. Notwithstanding the foregoing, Company will have no obligations under this Section 8.2 to the extent Losses arise from or occur as a result of or in connection with the (a) gross negligence or willful misconduct (including non-compliance
        with any applicable laws) on the part of a Rights Holder Party, or (b) breach by Rights Holder of any of its representations, warranties, covenants, or agreements set forth in this Agreement.</font></div>
    <div style="text-align: justify; text-indent: 81pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">8.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnification Procedures</u></font>. Each Party&#8217;s agreement to indemnify and hold the other harmless is conditioned upon the indemnified Party (a) providing written notice to the indemnifying Party of any
        claim, demand or action arising out of the indemnified activities within thirty (30) days after the indemnified Party has actual knowledge of such claim, demand or action, provided that no delay in providing such notice shall eliminate or reduce
        the indemnifying Party&#8217;s indemnification obligations hereunder except to the extent that such delay materially prejudices the indemnifying Party&#8217;s ability to defend or settle the applicable third party claim, (b) permitting the indemnifying Party
        to assume control over the investigation of and preparation and defense against any such claim, demand or action, (c) assisting the indemnifying Party, at the indemnifying Party&#8217;s reasonable expense, in the investigation, preparation and defense of
        any such claim, demand or action, and (d) not compromising or settling such claim, demand or action that&#160; </font>would require the indemnifying Party to admit liability, pay any amount or subject the indemnifying part to any restriction on its
      rights without the indemnifying Party&#8217;s prior written consent, which consent shall not be withheld, conditioned or delayed unreasonably. </div>
    <div style="text-align: justify; margin-right: 5.65pt; margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-7-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
    </div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-weight: bold;">9.&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Term and Termination</font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">9.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Term</u></font>. This Agreement shall commence on the Effective Date and, unless terminated earlier pursuant to Sections 9.2, 9.3 or 9.4 shall continue in full force and effect until the expiration of the
          Option Period (including any extensions thereof made by mutual written agreement of the Parties).</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">9.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Termination for Material Breach or Changed Circumstances</u></font>. If either Party materially breaches any of its representations, warranties or obligations under this Agreement at any time, the other Party
          shall have the right to terminate this Agreement by written notice to the breaching Party, if such material breach is not cured within thirty (30) days after written notice is given by such other Party to the breaching Party specifying the
          material breach, except that if less than thirty (30) days remain in the Option Period when such breach occurs, the applicable cure period shall be the period then remaining until the Termination Date. Company shall also have the right to
          terminate this Agreement in the event that: (i) Factor or Rights Holder materially breaches any of its representations, warranties or obligations under the Factor License Agreement, or the Factor License Agreement is otherwise is terminated, (ii)
          any material provision of the Factor License Agreement is amended, restated, waived or otherwise modified in a manner that would negatively impact the terms of the License Agreement if Company exercised the Option, as determined by Company in its
          sole and absolute discretion, (iii) any claim of infringement is asserted by a third party based on Exploitation of the Rights Holder, or (iv) any material change occurs with respect to the scope or extent of the Rights Holder Technology.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">9.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Additional Termination Rights</u></font>. This Agreement may be terminated by Company, in its sole discretion, upon written notice to Rights Holder.</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">9.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Survival</u></font>. Sections 1, 2, 6.3, 7, 8, 9.4, 10, and 11, and all obligations accruing prior to the termination of this Agreement shall survive any termination or expiration of this Agreement.
          Notwithstanding the foregoing, this Agreement will terminate in its entirety upon the execution by the Parties of the License Agreement.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Dispute Resolution</font>. In the event that a dispute arises between the Parties in the course of this Agreement, the dispute will be referred to the attention of the President of Company and
          the President of Rights Holder or their designees (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Executive Officers</u></font>&#8221;), provided that the same person shall not be the Executive Officer of both Parties involved
          in attempting to resolve such dispute. The Executive Officers will meet as soon as reasonably possible thereafter and in good faith attempt to resolve such dispute. If, within thirty (30) days after referral of such dispute to the Executive
          Officers by either Party, the Executive Officers are unable to resolve such dispute, either Party will have the right to have the dispute resolved by binding arbitration, initiated by either Party on ten (10) business days&#8217; notice to the other
          Party following the expiration of the thirty (30) day period referenced above (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Initiation Notice</u></font>&#8221;), under the Commercial Arbitration Rules of the American
          Arbitration Association (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>AAA</u></font>&#8221;) then pertaining (available at www.adr.org), except where those rules conflict with this provision, in which case this provision controls,
          applying the laws of the State of New York, without regards to its conflicts of law provisions, before three (3) independent, neutral arbitrators experienced in the pharmaceutical industry and licensing transactions in such industry. The place of
          arbitration shall be New York, New York. Company and Rights Holder shall each be entitled to select one (1) such arbitrator, with the two (2) such</font> arbitrators so selected selecting the third (3rd) such arbitrator. In the event either Party
        fails to select its arbitrator within ten (10) business days of the Initiation Notice, the arbitrator selected by the other Party within such ten (10) business day period shall be entitled to select such arbitrator. The arbitration shall be
        conducted in English. The decision of the arbitrators will be final and binding on the Parties, and any decision of the arbitrators may be enforced in any court of competent jurisdiction. Each Party shall bear its own expenses and an equal share of
        the reasonable, documented expenses of the arbitration panel and any fees required by AAA to submit such matter to arbitration, unless the panel determines that any such fees or expenses are to be paid by the non- prevailing Party. Notwithstanding
        the foregoing, either Party may seek injunctive, equitable, or similar relief from a court of competent jurisdiction as necessary to enforce its rights hereunder without the requirement of arbitration. </div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-8-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: 36pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; Miscellaneous.</div>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Assignment/Change of Control.</u></font> Neither Party shall assign this Agreement without the prior written consent of the other Party, provided, however, that a Party is permitted to assign this Agreement
          without such consent in connection with the transfer or sale of all or substantially all of its assets, capital stock or business related to this Agreement, or in the event of its merger or consolidation or change in control, corporate
          recapitalization or restructuring or similar transaction. Any permitted assignee must assume all obligations of its assignor under this Agreement. Any assignment by a Party of this Agreement in violation of this Section 11.1 shall be void.</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.2</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Severability.</u></font> If one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the Parties shall substitute, by mutual consent, valid provisions for such invalid,
          illegal or unenforceable provisions which valid provisions are, in their economic effect, sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such
          provisions. In the event that such provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one or more provisions of the Agreement shall not affect the validity of this Agreement as a whole.</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notices.</u></font> Any notice, consent or report required or permitted to be given or made under this Agreement by one Party to the other Party shall be in English and in writing, delivered personally or by
          email (receipt verified), facsimile or electronic transmission (including pdf), or by U.S. first class mail or express courier providing evidence of receipt, postage prepaid (where applicable), at the following address for a Party (or such other
          address for a Party as may be specified by like notice):</font></div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" align="" id="z02e786fdd3c24d899990838c5682e9ce" style="border-collapse: collapse; width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>To Company:</u></div>
              <div>&#160;</div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn Immunotherapeutics, Inc. </div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">10531 4S Commons Dr., Ste. 160-550 </div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">San Diego, CA 92127</div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Attn: Matthew Angel, PhD, CEO <br>
              </div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">mangel@brooklynitx.com </div>
            </td>
            <td colspan="1" style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>To Rights Holder:</u></div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u> <br>
                </u></div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Exacis Biotherapeutics Inc.</div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">1035 Cambridge Street, Suite 17B </div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cambridge, MA 02141</div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Attn: Gregory Fiore, MD, CEO<br>
                &#160;greg.fiore@exacis.com</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">All such notices, consents or reports shall be effective upon receipt.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.4</font>&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Applicable Law.</u></font> This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law principles</font> that would provide
        for application of the law of a jurisdiction other than the State of New York and excluding the United Nations Convention on Contracts for the International Sales of Goods. </div>
      <div style="text-indent: 81pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-9-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.5</font>&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Entire Agreement.</u></font> This Agreement (including the Exhibits attached hereto) contains the entire agreement by the Parties with respect to the subject matter hereof and supersedes any prior express or
          implied agreements, understandings and representations, either oral or written, which may have related to the subject matter hereof in any way.</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Interpretation.</u></font> The captions to the several Sections of this Agreement are not a part of this Agreement, but are included for convenience of reference and shall not affect its meaning or
          interpretation. In this Agreement: (a) the word &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221; or like expression; (b) the singular shall include the plural and <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">vice versa</font>; and (c) masculine, feminine and neuter pronouns and expressions shall be interchangeable.</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.7</font>&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Independent Contractors.</u></font> It is expressly agreed that Company and Rights Holder shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership,
          joint venture or agency or other fiduciary relationship. Neither Company nor Rights Holder shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other
          Party, without the prior written consent of the other Party to do so.</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.8</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Waiver; Amendment.</u></font> Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a written instrument executed by a duly authorized representative of
          the Party waiving compliance. The delay or failure of any Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party&#8217;s rights at a later time to enforce the same. This Agreement may be
          amended, and any term of this Agreement may be modified, only by a written instrument executed by a duly authorized representative of each Party.</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.9</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Binding Effect.</u></font> This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.</font></div>
      <div style="text-indent: 72pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.10</font>&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Counterparts.</u></font> This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
          Facsimile and other electronically scanned signatures shall have the same effect as their originals.</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[Signature Page Follows]</div>
      <br>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-10-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IN WITNESS WHEREOF</font>, the Parties hereto have caused their duly
        authorized representatives to execute this Option Agreement.</div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;" id="z20e2000e3ef2427391060405ab1ba415">

            <tr>
              <td colspan="3" rowspan="1">
                <div>
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exacis Biotherapeutics Inc.</div>
                </div>
              </td>
            </tr>
            <tr>
              <td colspan="3" rowspan="1"> <br>
              </td>
            </tr>
            <tr>
              <td style="width: 3%; padding-bottom: 2px;" colspan="1">By&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
                </font></td>
              <td style="border-bottom: 1px solid #000000; width: 40%;">
                <div><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Gregory Fiore</font></div>
              </td>
              <td style="width: 57%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="3"><br>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;">

            <tr>
              <td rowspan="1">Printed Name: Gregory Fiore </td>
            </tr>
            <tr>
              <td rowspan="1"><br>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 3%;">Title: Chief Executive Officer </td>
            </tr>
            <tr>
              <td rowspan="1"><br>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;">

            <tr>
              <td colspan="3" style="font-weight: bold;" rowspan="1">Brooklyn Immunotherapeutics, Inc.&#160;&#160;</td>
            </tr>
            <tr>
              <td colspan="3" rowspan="1"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 3%; padding-bottom: 2px;" rowspan="1">By</td>
              <td colspan="1" style="border-bottom: 1px solid #000000; width: 40%;" rowspan="1"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Matthew Angel</font></td>
              <td style="width: 57%; padding-bottom: 2px;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td colspan="3" rowspan="1"><br>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;">

            <tr>
              <td style="width: 3%;" colspan="2" rowspan="1">Printed Name:Matthew Angel&#160;</td>
            </tr>
            <tr>
              <td style="width: 3%;" colspan="2" rowspan="1"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 3%;" rowspan="1">Title:Interim Chief Executive Officer&#160;</td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div> <br>
        </div>
        <div style="text-align: center;"> <font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">-11-</font> </div>
      </div>
    </div>
  </div>
  <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>btx-20221008.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<xs:schema targetNamespace="http://brooklynitx.com/20221008" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:btx="http://brooklynitx.com/20221008" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20221008_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20221008_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>btx-20221008_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>btx-20221008_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.10.1.5080 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20221008.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139898306278944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  08,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Brooklyn ImmunoTherapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10355 Science Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.005 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>brhc10042946_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="btx-20221008.xsd" xlink:type="simple"/>
    <context id="c20221008to20221008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-10-08</startDate>
            <endDate>2022-10-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20221008to20221008"
      id="Fact_68b7d76f7f964222ab460f4b1530167e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20221008to20221008"
      id="Fact_33f2264cff6a4e068e2bf7c04c77161c">0000748592</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20221008to20221008"
      id="Fact_de22f9a747f64db399e4bfbc99373a61">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20221008to20221008"
      id="Fact_0969f57d8dba4f4d9e804a5a0b9c93ec">2022-10-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20221008to20221008"
      id="Fact_7b2ab6666e8d493abc0389dc286f6673">Brooklyn ImmunoTherapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20221008to20221008"
      id="Fact_4a367ad333b5400bb9e60812b94cdb1a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20221008to20221008"
      id="Fact_16058f036b7a4c56ac6b861efd7d7beb">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20221008to20221008"
      id="Fact_d5c2085f6b0947fd9b68b1b037a58791">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20221008to20221008"
      id="Fact_7cc25fa170bd49ba8eea86a14f8821c0">10355 Science Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20221008to20221008"
      id="Fact_ce12040db0414e1ebea5ae53da46be6b">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20221008to20221008"
      id="Fact_188fe3964e4446ad8a7d9f79662cb0a3">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20221008to20221008"
      id="Fact_889df62cb9274fa8bf3cd168b926ecf0">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20221008to20221008"
      id="Fact_8daa3f82782c49968167aa9e5df89040">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20221008to20221008"
      id="Fact_32794a5444c245cf907152a0b35b715f">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20221008to20221008"
      id="Fact_58726bb3ec3c4757bd218a30e348599c">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20221008to20221008"
      id="Fact_822153b6f2c2418e8771c417de6c8386">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20221008to20221008"
      id="Fact_c3ec0441730842f2a0e9b73c3114d70f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20221008to20221008"
      id="Fact_cd48834c5e474c209cbfdb1e57f86e9e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20221008to20221008"
      id="Fact_187f122d6c6f408a91d256c12475c5b6">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20221008to20221008"
      id="Fact_a77112c38be84e23b79341fee77f1241">Common Stock, par value $0.005 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20221008to20221008"
      id="Fact_840ee01ddc6445bf95352561d98dce9c">BTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20221008to20221008"
      id="Fact_6410edff7a5f4a558a24a1ab285f61f1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20221008to20221008"
      id="Fact_f4ec674725eb4bc9bd6ed98c60e6be12">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  WA$Y5EXJ[',
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M3E4<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y
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M%0:P;W(@"2[)E1M27>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04
M"  WA$Y5)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM
M?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(H
MND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++
M3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$
M%     @ -X1.5660>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&UL
MK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QX
MWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#
M4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$
MJ+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:
M!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U5
M9"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\
MUDX:?^:+X3]>?P%02P$"% ,4    "  WA$Y5!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #>$3E55
M!1?([@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( #>$3E697)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ -X1.57O:^L)R!
M3!$  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( #>$3E6?H!OPL0(  .(,   -              "  ;4,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ -X1.59>*NQS     $P(   L
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64$L%!@     )  D /@(  !44      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10042946_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10042946_8k.htm">brhc10042946_8k.htm</File>
    <File>brhc10042946_10-1.htm</File>
    <File>btx-20221008.xsd</File>
    <File>btx-20221008_lab.xml</File>
    <File>btx-20221008_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10042946_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10042946_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "btx-20221008_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btx-20221008_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "btx-20221008.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "btx",
   "nsuri": "http://brooklynitx.com/20221008",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10042946_8k.htm",
      "contextRef": "c20221008to20221008",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://brooklynitx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10042946_8k.htm",
      "contextRef": "c20221008to20221008",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001140361-22-037240-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-037240-xbrl.zip
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MJA9M&=6+%7=J3:=I)L82F)T9<_Y$(K[]FEMT I/F"3>#WOH T$&'N)='M%N
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MC1T6$"$!;9@Q#9%<(Z ^"N/3)"NB@XO[_1.RN9+M#0,9T/C(>&-BB8%_ >*
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M%U:+915\\MB:!]2JK,"[0 DC:FTAS['*1JDK=>3P::P4L69216N"L0 3G+,
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MCP^-7F><%F/Q1?OKPDL%-S/":0Y]JD];1+F=VJIJ@;S\?%AD1_5G58_#@E:
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MK_P6Y9/_WN5A7_P:[I'\@=QB$L&'_P=02P,$%     @ -X1.5:C5B--) P
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MP34XNZ78WHD=:5NNX)MID"SJ$>U5^TQ>N1U0'1C2Y**P>G=5(9=Q0.@3H=D
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M!;!&G_:9E3I6^ %CQ:246 -")2=7;$*F)BIU[4R&\; <PKM *A9/9D^2">J
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M+#4DM<;48A@Q>&+ZBF]0TABJGY2!W#>[9I6B+0^Y>1!J5:P(>,(V$VF0UYI
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MB'R1_]7^\#]02P$"% ,4    "  WA$Y5=0JKB]\U  !'+0$ %0
M    @ $     8G)H8S$P,#0R.30V7S$P+3$N:'1M4$L! A0#%     @ -X1.
M5=M<!)X"%   3GP  !,              ( !$C8  &)R:&,Q,# T,CDT-E\X
M:RYH=&U02P$"% ,4    "  WA$Y5J-6(TTD#  ! #P  $
M@ %%2@  8G1X+3(P,C(Q,# X+GAS9%!+ 0(4 Q0    ( #>$3E7'*RTR@ @
M '58   4              "  ;Q-  !B='@M,C R,C$P,#A?;&%B+GAM;%!+
M 0(4 Q0    ( #>$3E6&0#M_W@4  /<^   4              "  6Y6  !B
I='@M,C R,C$P,#A?<')E+GAM;%!+!08     !0 % $8!  !^7      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
